CD19 and B-cell non-Hodgkin lymphoma: Intermediate results of the greatest clinical studies of CD19-specific CAR-T cell treatment in highly malignant aggressive B-cell lymphoma (ZUMA-1, JULIET, TRANSCEND) show excellent response and controlled safety.